Correlation between E-Cad,G-17,HER-2 and postoperative recurrence risk of gastric cancer

doi:10.3969/j.issn.1673-8640.2022.01.008

Abstract

Abstract:

Objective To investigate the correlation between serum epithelial cadherin（E-Cad）and gastrin-17（G-17）levels and human epidermal growth factor receptor-2（HER-2） expression in tumor tissues and the risk of postoperative recurrence in patients with gastric cancer. Methods Totally,92 patients with gastric cancer who underwent radical gastric cancer treatment were enrolled,and the serum E-Cad and G-17 levels and the tumor tissue HER-2 expression were determined before the operation. All the patients were followed up for 5 years,with gastric cancer recurrence or 5 years of follow-up as the follow-up endpoint. Totally,92 patients with benign gastric lesions were enrolled as control group. The clinical data（sex,age,clinical stage,degree of differentiation,recurrence and so on） of all the gastric cancer patients were collected. Receiver operating characteristic（ROC） curve was used to evaluate the efficiency of various indicators in judging the recurrence of gastric cancer. Cox regression analysis was used to evaluate the risk factors affecting the recurrence of gastric cancer. Kaplan-Meier survival curve was used to evaluate the 5-year recurrence of gastric cancer. Results The serum G-17 level and the positive rate of HER-2 in gastric cancer group were higher than those in control group（P=0.000）,and the serum E-Cad level was lower than that in control group（P=0.000）. The levels of serum E-Cad and G-17 and the positive rate of HER-2 were correlated with TNM stage,differentiation and recurrence of gastric cancer（P<0.05）,but there was no correlation with sex（P>0.05）. ROC curve analysis showed that the areas under curves（AUC） of single determinations of E-Cad,G-17 and HER-2 and combined determination were 0.775,0.822,0.603 and 0.950,respectively. Kaplan-Meier survival curve analysis showed that the recurrence rate of low expression of E-Cad was higher than that of high expression group（P<0.05）,while the recurrence rate of low expression of G-17 and low expression of HER-2 was lower than that of high expression of G-17 and high expression of HER-2（P<0.05）. Cox regression analysis showed that decreased E-Cad level,increased G-17 level and increased HER-2 expression were risk factors for gastric cancer recurrence [hazard ratios（HR） were 0.835,1.568 and 3.981,95% confidence intervals（CI） were 0.767-0.909,1.292-1.904 and 1.504-10.538,respectively]. Conclusions E-Cad,G-17 and HER-2 play roles in the prediction of gastric cancer recurrence after radical gastric cancer treatment.

Key words: Epithelial cadherin, Gastrin-17, Human epidermal growth factor receptor-2, Gastric cancer, Recurrence

CLC Number:

R446.1

MAO Zheng, QIAN Zengkun, YING Fei, WANG Zhaoli, XIAO Qun, CUI Fan. Correlation between E-Cad,G-17,HER-2 and postoperative recurrence risk of gastric cancer[J]. Laboratory Medicine, 2022, 37(1): 41-46.

Figures/Tables 8

References 19

[1]	刘苗, 王英南, 张韶辰, 等. 影响胃癌根治术后早期复发的危险因素分析[J]. 临床肿瘤学杂志, 2020, 25(10):905-910.
[2]	刘苗, 王英南, 赵群, 等. 不同Lauren分型胃癌的临床病理特征及影响胃癌根治术后复发的危险因素分析[J]. 中国肿瘤, 2019, 28(12):941-950.
[3]	MA L, YANG R, GU J, et al. The expression of AGGF1,FOXC2,and E-cadherin in esophageal carcinoma and their clinical significance[J]. Medicine(Baltimore), 2020, 99(37):e22173.
[4]	SYMMANS W F, WEI C, GOULD R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype[J]. J Clin Oncol, 2017, 35(10):1049-1060. DOI URL
[5]	POKHAREL K, GILBAR P J, MANSFIELD S K, et al. Elevated beta human chorionic gonadotropin in a non-pregnant female diagnosed with anal squamous cell carcinoma[J]. J Oncol Pharm Pract, 2020, 26(5):1266-1269. DOI URL
[6]	ZHAO W X, LIU Z F, LI X L, et al. Correlations of serum homocysteine,VEGF and gastrin 17 with gastric cancer and precancerous lesions[J]. Eur Rev Med Pharmacol Sci, 2019, 23(10):4192-4198.
[7]	ZHOU N, GUO X, YANG M, et al. ⁶⁸Ga-ZHER2 PET/CT reveals HER2-positive metastatic gastric cancer with better image quality than ¹⁸F-FDG[J]. Clin Nuclear Med, 2020, 45(2):e101-e102. DOI URL
[8]	ULASE D, HECKL S, BEHRENS H M, et al. Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference[J]. Histopathology, 2020, 76(3):433-446. DOI URL
[9]	BAROK M, LE JONCOUR V, MARTINS A, et al. ARX788,a novel anti-HER2 antibody-drug conjugate,shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer[J]. Cancer Lett, 2020, 473:156-163. DOI URL
[10]	张自森, 巴楠, 张剑, 等. 胃癌FOLFOX4方案化疗患者预后与血清可溶性E-钙黏蛋白表达的关系[J]. 中华实验外科杂志, 2016, 33(12):2773-2775.
[11]	张毅, 张君薇. 血清E-Cad、PGⅠ、CEA和CA19-9单独和联合检测对胃癌诊断的临床价值[J]. 实用癌症杂志, 2018, 33(3):370-372.
[12]	陈玲, 林晶, 王晓杰, 等. 人类表皮生长因子受体2在胃癌根治术后复发患者中的表达及其意义[J]. 肿瘤研究与临床, 2020, 32(3):178-181.
[13]	TORABIZADEH Z, NOSRATI A, SAJADI SARAVI S N, et al. Evaluation of E-cadherin expression in gastric cancer and its correlation with clinicopathologic parameters[J]. Int J Hematol Oncol Stem Cell Res, 2017, 11(2):158-164.
[14]	LIN Z, BIAN H, CHEN C, et al. Application of serum pepsinogen and carbohydrate antigen 72-4(CA72-4) combined with gastrin-17(G-17) detection in the screening,diagnosis,and evaluation of early gastric cancer[J]. J Gastrointest Oncol, 2021, 12(3):1042-1048. DOI URL
[15]	WANG Y, ZHU Z, LIU Z, et al. Diagnostic value of serum pepsinogen Ⅰ,pepsinogen Ⅱ,and gastrin-17 levels for population-based screening for early-stage gastric cancer[J]. J Int Med Res, 2020, 48(3):300060520914826.
[16]	董曲文, 陈晓, 丁纪元. 早期胃癌患者内镜黏膜下剥离术前后血清胃泌素-17、糖类抗原-125及胃蛋白酶原水平的变化和意义[J]. 中国内镜杂志, 2020, 26(2):37-42.
[17]	PALLE J, ROCHAND A, PERNOT S, et al. Human epidermal growth factor receptor 2(HER2) in advanced gastric cancer:current knowledge and future perspectives[J]. Drugs, 2020, 80(4):401-415. DOI URL
[18]	KANAYAMA K, IMAI H, USUGI E, et al. Association of HER2 gene amplification and tumor progression in early gastric cancer[J]. Virchows Arch, 2018, 473(5):559-565. DOI URL
[19]	KIM S, KIM Y J, CHUNG W C. HER-2 positivity is a high risk of recurrence of stage Ⅰ gastric cancer[J]. Korean J Intern Med, 2021, 36(6):1327-1337. DOI URL

组别	例数	E-Cad/ （ng/mL）	G-17/ （pg/mL）	HER-2阳性/ [例（%）]
胃癌组	92	20.92±5.11	25.68±6.33	27（29.35）
对照组	92	32.76±4.14	10.67±3.22	5（5.43）
统计值		17.268	20.272	20.950
P值		0.000	0.000	0.000

组别	例数	E-Cad/ （ng/mL）	G-17/ （pg/mL）	HER-2阳性/ [例（%）]
胃癌组	92	20.92±5.11	25.68±6.33	27（29.35）
对照组	92	32.76±4.14	10.67±3.22	5（5.43）
统计值		17.268	20.272	20.950
P值		0.000	0.000	0.000

临床病理参数	例数	E-Cad/（ng/mL）	G-17/ （pg/mL）	HER-2阳性/ [例（%）]	临床病理参数	例数	E-Cad/ （ng/mL）	G-17/ （pg/mL）	HER-2阳性/ [例（%）]
性别					分化情况
男性	55	20.47±0.30	26.37±1.41	15（27.27）	低分化	35	16.42±5.88	23.09±5.14	2（5.71）
女性	37	20.42±0.21	26.09±1.46	12（32.43）	中分化	30	19.10±4.87	26.08±5.17	4（13.33）
统计值		0.940	0.914	0.123	高分化	27	22.10±4.87	29.55±5.17	21（77.78）
P值		0.350	0.360	0.940	统计值		12.090	11.202	17.989
TNM分期					P值		0.000	0.000	0.000
Ⅰ~Ⅱ期	45	17.01±5.42	23.69±1.15	5（11.11）	是否复发
Ⅲ~Ⅳ期	47	22.03±5.55	29.79±1.14	22（46.81）	复发	25	18.74±5.37	28.33±1.33	18（72.00）
统计值		4.389	24.704	11.222	未复发	67	21.73±5.51	24.69±1.57	9（1.00）
P值		0.000	0.000	0.000	统计值		2.359	16.968	30.122
					P值		0.020	0.000	0.000

临床病理参数	例数	E-Cad/（ng/mL）	G-17/ （pg/mL）	HER-2阳性/ [例（%）]	临床病理参数	例数	E-Cad/ （ng/mL）	G-17/ （pg/mL）	HER-2阳性/ [例（%）]
性别					分化情况
男性	55	20.47±0.30	26.37±1.41	15（27.27）	低分化	35	16.42±5.88	23.09±5.14	2（5.71）
女性	37	20.42±0.21	26.09±1.46	12（32.43）	中分化	30	19.10±4.87	26.08±5.17	4（13.33）
统计值		0.940	0.914	0.123	高分化	27	22.10±4.87	29.55±5.17	21（77.78）
P值		0.350	0.360	0.940	统计值		12.090	11.202	17.989
TNM分期					P值		0.000	0.000	0.000
Ⅰ~Ⅱ期	45	17.01±5.42	23.69±1.15	5（11.11）	是否复发
Ⅲ~Ⅳ期	47	22.03±5.55	29.79±1.14	22（46.81）	复发	25	18.74±5.37	28.33±1.33	18（72.00）
统计值		4.389	24.704	11.222	未复发	67	21.73±5.51	24.69±1.57	9（1.00）
P值		0.000	0.000	0.000	统计值		2.359	16.968	30.122
					P值		0.020	0.000	0.000

项目	AUC（95%CI）	最佳临界值	敏感性/%	特异性/%	敏感性/%	阳性预测值/%	阴性预测值/%	Youden指数
E-Cad	0.775（0.520~0.872）	15.32 ng/mL	92.59	40.48	92.59	34.25	89.47	33.07
G-17	0.822（0.230~0.974）	22.71 ng/mL	81.48	51.11	81.48	34.38	82.14	32.59
HER-2	0.603（0.600~0.746）	2+	88.89	35.14	88.89	31.58	81.25	24.03
联合检测	0.950（0.112~0.965）	0.64	77.78	74.07	77.78	80.77	90.91	51.85